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Abstract
Background: High grade serous ovarian cancer is characterised by high initial response to chemotherapy but
poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease
is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated
with p53 accumulation. TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift
or splice-site mutations associated to complete absence of p53 expression. Different studies show that this
kind of tumors may have a worse prognosis than other TP53 mutated HGSC.
Methods: In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC
consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome
sequencing and comparative genome hybridisation.
Results: Significant heterogeneity was found among the different tumor samples, both at the mutational and
copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three
samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples.
Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and
the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that
most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1.
Using functional annotation and network analysis, we identified those biological functions most significantly
altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid
metabolism emerged as important for tumor development and progression, suggesting its potential interest
as therapeutic targets.
Conclusions: Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the
most aggressive subpopulations and at least some of the genes that may be implicated in its progression
and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out
genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover
possible therapeutic strategies.
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Background
Ovarian cancer is the most common cause of death from
gynecological malignancies. Around seventy percent of
ovarian cancers are histologically classified as high-grade
serous carcinoma (HGSC). The standard treatment for
these tumors is cytoreductive surgery followed by
platinum-taxane chemotherapy. Although the initial
response rate is higher than 80 %, the majority of
patients relapses within five years and die due to
chemo-resistant disease [1, 2].
HGSCs are characterised by nearly universal TP53
gene mutation, present in more than 95 % of the cases
[3]. The most common TP53 abnormalities are missense
mutations, which induce nuclear accumulation of the
mutant protein with a strongly positive IHC staining.
However, approximately 30 % of somatic TP53 mutations
are considered null mutations that lead to complete ab-
sence of p53 protein due to nonsense, frameshift or
splicing junction mutations [4]. The prognosis value of
TP53 status is a controversial issue [5]. Nevertheless,
several studies support that tumors with TP53 null mu-
tations present a worse outcome compared with those
in which TP53 harbors mutations involving overexpres-
sion. This would happen not only in ovarian cancers
[6–9], but also in breast, colorectal and head and neck
cancers and leukemia [10].
The Cancer Genome Atlas (TCGA) consortium has
enabled a deeper understanding of HGSCs using an inte-
grated genomic approach for the analysis of 316 tumors.
This study has revealed that, with the exception of TP53
mutation, present in 96 % of the tumors, recurrent
mutations are not common in HGSCs. Nonetheless the
hallmark of HGSCs was numerous somatic copy number
alterations, with more than 100 recurrent amplifications
and deletions identified [11]. However, this analysis only
considered primary tumors samples, regardless of subse-
quent recurrences. In fact, there are few studies that
have analysed from a genomic point of view the evolu-
tion of these tumors using paired samples of primary
tumor and post-treatment relapse. According to some of
these studies, primary and recurrent diseases would be
genetically similar [12–14]. Conversely, other studies
have shown a high degree of intra-tumor heterogeneity,
which would allow clonal evolution and the successive
tumor progression and resistance to chemotherapy
[15, 16]. In fact, intra-tumor heterogeneity has been
shown to be intrinsic to primary tumor and not just
a result of chemotherapy treatment [14, 17].
To the best of our knowledge, none of these studies
considered TP53 null tumors as an individual clinical
entity. In the present study, whole-exome sequencing
and comparative genomic hybridisation was performed
on primary tumor and recurrence implants of a TP53
null patient, revealing significant heterogeneity between
all samples. Selected variants detected in the genomic
analysis were subsequently validated in multiple
tumoral implants from the primary tumor and the
recurrence. These data revealed intra-tumor hetero-
geneity in the primary tumor, which was reflected in
the different recurrence metastases, suggesting a
model of clonal evolution.
Methods
Samples selection
Tumoral samples from primary and recurrence disease
were selected from a TP53 null case of HGSC. Biospe-
cimens and clinical data were collected after written
approval of the study by the Ethics Committee of the
MD Anderson Cancer Center. A specific informed
consent was obtained from the patient managed by the
MD Anderson Foundation Biobank (record number
B.0000745, ISCIII National Biobank Record) and in-
cluded the authorization for data publication of individ-
ual clinical data and any accompanying images. A total
of twelve samples were selected, three frozen and nine
Formalin-Fixed Paraffin-Embedded (FFPE) tissue. Six
primary tumor (P1-P6), two intra-pelvic recurrence
(IR1-IR2) and four extra-pelvic recurrence (ER1-ER4)
implants were analysed (Fig. 1a). All samples selected
contained at least 80 % of tumoral cells. Non-tumoral
mesothelium (N) was used as control tissue.
Immunohistochemistry
Immunostaining was performed on 2 μm FFPE tissue
sections. Deparaffinisation and antigen retrieval were
done in a PT Link module (Dako, Denmark) and
immunohistochemistry was done in an Autostainer
(Dako). Primary antibodies used were WT1 (clone
6 F-H2, RTU, 1:1, Dako), PTEN (clone 6H2.1, 1:100,
Dako), p53 (clone DO-7, RTU, 1:1, Dako) and Ki-67
(clone MIB-1, RTU, 1:1, Dako). Amplification and
visualisation of immune complexes and counterstain-
ing were also performed in the Autostainer with the
use of an EnVision FLEX+, Mouse (Dako, CA, USA).
Slides were counterstained with hematoxylin and
evaluated by two independent pathologists.
Whole-exome sequencing (WES)
Whole-exome sequencing was performed in four frozen
samples (N, P1, IR1 and ER1) using the latest version of
SureSelectXT Human All Exon V4 + UTR (71 Mb)
enrichment kit and SOLiD high-throughput sequencing
platform, according to manufacturer’s protocols. Seq-
uencing reactions were carried out to obtain read pairs
(75 + 35 nt, paired-end). Data quality was estimated
using parameters from SETS (SOLiD Exerimental
Tracking System) software. For the bioinformatics
analysis, see Additional file 1: Supplementary Materials.
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Fig. 1 (See legend on next page.)
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Variant calling for Single Nucleotide Variants (SNVs)
identification was performed using three different
algorithms: VarScan2 [18], Mutect [19] and Bioscope.
‘In-house’ scripts were developed to combine the
variants and filter possible technical artifacts. SNVs
and Indel identified were annotated using the ‘Appli-
caton Programming Interfaces’ (APIs) from Ensembl
v64 and several ‘custom’ scripts. SNVs and Indel
with a minimum coverage of 10 and frequency above
0.1 percent were selected. Variants consequences were
analysed using Condel [20] (http://bg.upf.edu/fannsdb/),
SIFT [21] (http://sift.jcvi.org) and PolyPhen [22] (http://
genetics.bwh.harvard.edu/pph2/) predictors.
SNVs Validation
A total of 25 variants detected by whole-exome
sequencing were reanalysed by Sanger sequencing.
PCR conditions and length of amplicons are indicated
in Additional file 1: Table S2.
Comparative genomic hybridisation (CGH)
CGH was performed according to Kallioniemi et al. [23],
with some modifications. Tumor and normal DNA were
labeled using a nick translation kit (Abbott Molecular
Inc.). In short, 200 ng of each labeled DNA was hybri-
dised to normal female metaphase cells in the presence
of 20–35 mg of Cot-1 DNA for 3 days. After washes, the
chromosomes were counterstained with DAPI in an
antifade solution. Analysis was performed with a Leica
DM4500 epifluorescence microscope equipped with a
CCD camera. A minimum of 15 metaphase cells per
hybridisation per case were analysed by use of the
CytoVision System with version 7.3.1 high-resolution
CGH analysis software (Leica Biosystems, UK). The
CGH profiles were compared to a dynamic standard
reference interval on the basis of an average of normal
cases, as previously described [24].
Fluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation was performed as
previously described [24]. Briefly, metaphase chromosomes
were prepared directly from the same samples used for
CGH. Slides were placed at 90 °C for 10 min, dehydrated
through a series of ethanol washes, and denatured in the
presence of a probe on a plate at 75 °C for 1 min. For detec-
tion of gene amplification, gene-specific probes for PML
and RARA (used as control) (Vysis, Downers Grove, IL)
were used. At least 100 interphase nuclei were analysed.
Functional annotation
The selected variants were annotated using David proto-
cols [25, 26]. Briefly, this method allows the functional
annotation of genes using different biological database
as Biocarta (http://www.biocarta.com/), Gene Ontology
(http://geneontology.org/), KEGG (http://www.genome.jp/
kegg/pathway.html) and Reactome (http://www.reacto-
me.org/). The interesting functional categories were
selected using a p-Value threshold of 0.2. Finally, the
correlation between genes and functional categories
was represented in form of network using Cytoscape
tool [27].
Hierarchical clustering
A hierarchical clustering method was applied to group the
samples on the basis of similarities in mutation pattern.
The unsupervised analyses were carried out using the
SPSS 17.0 for statistical program (SPSS Inc., Chicago, IL)
assuming Euclidean distances between mutations.
Results
Clinical history and case description
The patient of this study was diagnosed in 2009 at age
50 with a stage IIIC high grade serous carcinoma
(HGSC) with extensive intra- and extra-pelvic peritoneal
carcinomatosis. After surgical primary cytoreduction the
patient was left with residual disease of less than 1 cm.
Afterwards she was included in the OCTAVIA clinical
trial [28] and treated with six cycles of weekly paclitaxel
and carboplatin, with bevacizumab every 3 weeks for a
total period of 12 months. Patient relapsed after
23 months of platinum free interval with numerous
tumor implants in intra- and extra-pelvic peritoneum
(Fig. 1a). The patient underwent a second debulking
surgery without residual macroscopic disease followed
by 6 cycles of carboplatin and pegylated liposomal
doxorubicin hydrochloride (Fig. 1b).
Both primary and relapsed tumors showed papillary
patterns with frequent necrosis, nuclear expression of
WT1 and very high proliferative rate (90 % as deter-
mined by Ki-67 staining). Immunohistochemistry also
showed lack of PTEN expression (suggestive of muta-
tion) and complete absence of p53 staining (indicative of
null mutation). Sanger sequencing showed a mutation in
exon 7 of TP53 resulting in a premature stop codon in
the position 234 of the protein (Fig. 1c). According to
these data, this tumor is classified as a TP53 null high
grade serous carcinoma.
(See figure on previous page.)
Fig. 1 Clinical case and sample description of an ovarian TP53 null HGSC. a Anatomical location of the primary tumor (blue) and recurrence
samples (intra-pelvic samples in green and extra-pelvic samples in red). b Patient’s clinical course. Grey squares indicate periods of treatment
between primary tumor diagnosis and relapse. c Representative images of hematoxilin/eosin staining (A) and immunohistochemistries for
WT1 (B), Ki-67 (C), PTEN (D) and p53 (E). TP53 mutation detected by Sanger sequencing (F) and its consequence in p53 protein (G)
Mota et al. BMC Cancer  (2015) 15:940 Page 4 of 11
Identification of somatic nucleotide variants by whole-
exome sequencing shows differences in the mutational
patterns of distinct tumor regions
In order to detect somatic nucleotide variants, whole-
exome sequencing was performed in the primary tumor
(P1), pararectal recurrence implant (IR1), ileal recur-
rence implant (ER1) and mesothelium as normal tissue
(N) from a TP53 null patient. After comparison of
tumoral samples with the normal tissue, the bioinfor-
matic analysis identified 102 variants, 99 SNVs and three
deletions (Additional file 1: Table S1). Only 42 variants
were common to all samples, comprising just 41 % of
the total. Sample specific variants were identified in the
three regions, as well as variants common to two
samples (Fig. 2a). Notably, the range of frequencies
found in the primary tumor variants suggested the
existence of intra-tumor heterogeneity from the onset.
The consequence of each variant in the corresponding
protein was analysed by the computational predictors
Condel, SIFT and Polyphen [20–22]. A total of 80
variants presented a possibly damaging or deleterious
consequence as predicted by at least one of them
(Fig. 2b). Interestingly, the scattering of these variants
reflects the unequal distribution of the mutations poten-
tially implicated in tumor progression.
A selection of 25 variants detected by WES was reana-
lysed by Sanger sequencing. Four of them were not
validated, showing a false positive rate of 16 % in the
WES study (Additional file 1: Table S2). The TP53
nonsense mutation was detected ubiquitously in the
three samples analysed, consistent with the founder role
of this gene in this type of cancer.
Copy Number Variations (CNVs) are unequally distributed
among the different tumor regions
HGSCs are characterised by high chromosomal instability
and widespread copy number changes. In order to analyse
copy number variations (CNVs), Comparative Genomic
Hybridisation (CGH) was performed in the primary tumor
(P1) and two recurrence implants (IR1 and ER1), using
normal tissue (N) as a reference. We identified changes in
18 chromosomal regions, with gain of material more
frequent than loss (61 % vs. 39 %) (Fig. 3, Additional file 1:
Table S3). A total of 7 changes (38 % of total) were com-
mon to the three samples, counting five gains (2q32q33,
3q22q29, 7q22q32, 8q12q24 and 11q14q22) and two
diminished regions (6q25q27 and depletion of whole
chromosome 4). P1 and ER1 shared 5 regions (gain
of 1p22p35 and 9q31, and loss of 17p13 and depletion of
whole chromosomes 12 and 16), while specific changes of
each sample were detected (8p22p23 and 15q22q26 in P1;
16q24 in IR1; and 5p15, 10q22 and 22q13 in ER1).
Interestingly, no changes exclusively common to P1 and
IR1 or to IR1 and ER1 were found.
The analysis of additional tumor regions shows the
existence of mutationally heterogeneous tumor clones
To further investigate intra-tumor heterogeneity, a
subset of 20 of the variants detected by exome sequen-
cing was validated by Sanger sequencing in the four
original samples (N, P1, IR1, ER1) and in nine additional
FFPE samples of tumor implants representing different
regions of the primary tumor and recurrences (P2-P6,
IR2, ER2-ER4) (Fig. 4a). For the location of the different
tumor regions, see Fig. 1a. Variants analysed were
selected to represent the different distributions identified
in whole-exome sequencing: nine ubiquitous (TP53,
CSMD3, CTC1, FAP, KIF21B, LAMA2, SMG7, UBR3 and
ZFAT), one shared by P1 and IR1 (FRMPD1), four
shared by IR1 and ER1 (HEPHL1, KIF21A, OR56B1 and
ZNF664), three P1 specific (CNOT1, PLXNA1 and
TRERF1), two IR1 specific (ROBO2 and TFDP1) and one
ER1 specific (GPNMB). All these variants were poten-
tially damaging, nonsense, frameshift or splice site
variants (Additional file 1: Table S1).
As expected some variants were detected in all of the
analysed samples, consistent with the exome sequencing
results in which they were detected ubiquitously in P1,
IR1 and ER1 samples (Fig. 4a). However, other variants,
also ubiquitous according to exome sequencing, were
not present in all the samples. Moreover, the FRMPD1
variant, originally presented in primary tumor and IR1
samples and not in ER1, was current not only in all pri-
mary and intra-pelvic regions but also in the other
extra-pelvic recurrence samples analysed.
On the other hand, some of the variants initially de-
tected variants as characteristic of them were detected
not only in new intra- and extra-pelvic recurrences, but
also in primary tumor regions different from the one ori-
ginally analysed. Moreover, ZNF664 mutation, (common
in IR1 and ER1 samples) was also found mutated in all
of the recurrence samples but not in the primary tumor.
Specific sample variants were also detected by Sanger se-
quencing, both for the primary tumor and for intra- and
extra-pelvic recurrences, showing a certain degree of
mutational heterogeneity among the different tumor
locations.
Additionally, intra-tumor genomic heterogeneity was
studied by fluorescence in situ hybridisation (FISH) in
PML gene (15q22), exclusively altered in P1 sample re-
garding CGH results (Additional file 2: Figure S1). PML
gain was observed by FISH in P1 but not in IR1 and
ER1 samples, confirming CGH data. Furthermore, het-
erogeneous CNVs were observed in FFPE samples ana-
lysed. While P3, P4, P5 and ER1 samples showed 3 or 4
copies of PML; P2, P6, IR2 and ER4 presented between
5 and 8 copies. ER3 sample presented just one copy of
PML per cell, indicating a deletion of this gene in this
specific tumor sample (Additional file 2: Figure S1).
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Therefore intra-tumor heterogeneity was not only ob-
served in genetic variations but also in genomic changes.
Hierarchical clustering according to mutation pattern
allows determining clonal evolution
Since the mutational heterogeneity observed in this
tumor is consistent with a clonal composition, we
performed a hierarchical clustering analysis based in the
distribution of the subset of 20 variants among the 12
different regions of the primary tumor and the two
recurrences (Fig. 4b). This analysis shows the existence
of two main branches, as shown in the diagram. Most of
the recurrences regions would evolve from a primary
tumor ancestor subpopulation that gives rise to the
upper branch, originating P3, P4 and P5 regions of the
primary tumor, the intra-pelvic recurrences and most of
the extra-pelvic. Notably, ER2 seems to be more closely
related to the intra-pelvic recurrence than to the other
extra-pelvic regions. The lower branch contains P1 (the
closest region to normal tissue), P2 and P6, and ER3
which would arise from this latter primary tumor region.
Remarkably, it is also possible to hierarchically cluster
the three original tumor regions (P1, IR1 and ER1)
according to the WES or CGH results. This tumor
phylogenetic tree is equivalent to the one generated with
the previous subset of 20 mutations, showing two
main branches, one corresponding to the primary
tumor (P1 region) and the other subdivided in two
sub-branches which contain each of the recurrences
samples (data not shown).
Functional annotation and network analysis identifies
biological functions implicated in tumor development
and progression
In order to analyse from a global point of view the
biological and molecular functions implicated in the de-
velopment and progression of this tumor, the functions of
the genes mutated according to the exome sequencing
were annotated using different biological databases as
Biocarta, Gene Ontology, KEGG and Reactome (see
Methods section). Network analysis using Cytoscape
plugin [27] identified cell adhesion, cell cycle control,
microtubule-related movement and transport, lipid me-
tabolism and apoptosis as pathways containing multiple
mutated genes (Fig. 5, Additional file 1: Table S4).
Fig. 2 Somatic variants detected by whole-exome sequencing in
a TP53 null HGSC. a Venn diagram showing the distribution of
the total number of variants among the different tumor samples
(P1, primary tumor: blue; IR1, intrapelvic recurrence sample: green; ER1,
extrapelvic recurrence sample: red). b Genes with missense, splice site,
nonsense or frameshift mutations with a negative consequence
in the corresponding protein and its distribution in the different
analysed samples
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Cell adhesion was consistently affected in all the
analysed samples, both with mutations common to all
samples and with shared or sample specific alterations.
Something similar, but with a lower number of affected
genes, occurred with cell cycle control, microtubule-based
movement, cell division and chromosome partitioning
and apoptosis. On the other hand, mutations in genes
implicated in lipid metabolism were mainly ubiquitous,
pointing to its possible involvement in tumor initiation. In
addition, functional annotation was also performed in
CGH data, identifying multiple genes implicated in the
previous described pathways (data not shown).
Interestingly, although DNA repair pathway is fre-
quently defective in these tumors, we did not identify
mutated genes directly related to this pathway. The
gene most closely related to this function was SETX,
which participates in the defense against oxidative
DNA damage [29]. However, CGH data showed that
multiple mismatch repair genes, such as RPA, POLE,
POLD3 or POLD4, exhibited copy number changes in
all the samples analysed (data not shown).
Discussion
Despite of initial response to treatment, the majority of
HGSC patients will recur and die due to chemoresistant
disease. It is well established that a defective status of
the DNA repair machinery (especially BRCA1/2 genes)
correlates with a better response to platinum-based
therapy [30]. Nevertheless, there is still a huge gap
regarding the genetic and molecular factors that contrib-
ute to explain the high rate of therapy failure in this
disease. Regarding the importance of TP53 status in this
disease, there are evidences pointing to a worse progno-
sis for tumors with null mutations compared with those
in which overexpression inducing mutations are found,
although this remains controversial [6–8, 10]. To this
respect, a meta-analysis of the genomic data generated
by the TCGA consortium regarding ovarian cancer
shows decreased overall and progression-free survival
for wild type TP53 tumors with respect to mutant
TP53 cases [31]. Taking this into account, we divided
the TP53 mutant group analysed in the TCGA study
into two subgroups: mutant and null tumors. TP53
null tumors are characterised by complete absence of
p53 protein, probably due to degradation of their
mRNAs by nonsense-mediated RNA decay [32]. Accord-
ingly, those cases with frameshift, splice site or nonsense
mutations and with a mRNA level z-score lower than -1
were classified as TP53 null tumors. This subgroup shows
an intermediate overall survival between the wild-type and
mutant groups, with nearly significant and equivalent
differences between the different categories (data not
shown). In view of that, a deeper understanding of TP53
null tumors would be needed.
In this study we have analysed by WES and CGH the
genetic and genomic alterations of an ovarian TP53
null HGSC case consisting of the primary tumor, one
intra-pelvic and another extra-pelvic recurrence. The
exome sequencing analysis shows a significant muta-
tional divergence between the primary tumor and both
recurrences. Nevertheless, this degree of divergence
decreases when other tumor regions are screened by
Fig. 3 Copy Number Variants (CNVs) detected by comparative genomic hybridisation (CGH) in a TP53 null HGSC. a Venn diagram showing the
distribution of the total number of copy number changes among the different samples ((P1 primary tumor: blue; IR1,intrapelvic recurrence sample: green;
ER1, extrapelvic recurrence sample: red). b Circes representation of the copy number changes. P1, ER1 and IR1 samples are displayed in concentric circles
(from the outside to the inside). Enhanced regions are represented in red and diminished regions in green
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Sanger sequencing for some of the mutations detected in
the exome analysis. The conclusions of this analysis are
consistent with a situation in which the primary tumor is
composed by mutationally heterogeneous clones, some of
which give rise to the recurrences. This heterogeneity is
intrinsic to the primary tumor and therefore not expected
to be a consequence of the therapy, consistently with what
has been previously reported for platinum-based treat-
ment [14]. The hierarchical clustering of the different
tumor regions allows to dissect the tumor clonal evolu-
tion. The primary tumor regions P3-P5-P4 are the most
closely related to the recurrences, with an ancestor tumor
subpopulation that would give rise to these primary
regions, both intra-pelvic recurrent locations and most of
the extra-pelvic (ER1, ER2 and ER4). However, it is worth
noting that while the intra-pelvic recurrence seems to have
evolved entirely from this ancestor, there is a region of the
extra-pelvic recurrence which is more closely related to
the other evolutionary branch of the tumor, which gives
rise to P1, P2, P6 and, apparently deriving from the latter,
ER3. This fact could be regarded as a reflect of a possibly
heterogeneous origin for the extra-pelvic recurrence or
either as an artifact of the hierarchical clustering process,
which does not take into account the CNVs observed in
this tumor. Even if the latter is the case, the extra-pelvic
recurrence is composed of two distinct subpopulations,
one derived from the ancestor clone that gives rise to the
upper evolutionary branch (ER1 and ER4) and the other
one derived from the intra-pelvic recurrence (ER2), having
acquired the ability to migrate to the extra-pelvic area.
As determined by functional annotation and network
analysis, cell adhesion and cell cycle control are clearly
Fig. 4 Intra-tumoral mutational pattern and hierarchical clustering to establish a clonal evolution in a TP53 null HGSC. a Selected variants
detected by whole-exome sequencing were reanalysed in 12 tumoral samples (P: Primary tumor, IR: intrapelvic recurrence, ER: extrapelvic
recurrence) and normal tissue (N) by Sanger sequencing. b Hierarchical clustering of the analysed samples on the basis of the similarities
in mutation pattern
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affected in this tumor. These functions are intrinsic to
tumor growth and spread, and therefore its malfunction
could be expected. Some of the genes related to cell adhe-
sion altered in this tumor have been previously reported
as related to tumor progression. Down regulation and
mutations in ROBO2 have been reported in prostate,
gastric and colorectal cancers [33, 34]; while LAMA2
down regulation has been reported in drug-resistant
ovarian cancer cell lines [35]. Moreover the silencing of
TRO, coding for trophinin, has been related to cisplatin
resistance and increased invasiveness of ovarian cancer
cells [36]. Conversely GPNMB, a migration-related gene,
is frequently overexpressed in triple negative breast
cancer among others [37]. Interestingly, GPNMB is
only mutated in ER1 and ER4, suggesting an important
role for this gene in the appearance of extra-pelvic re-
currence in this patient. Cell proliferation and cell cycle
control are also significantly altered in this tumor, not
only by gene mutation but also by copy number
changes. TFDP1, mutated only in the intra-pelvic recur-
rences regions, participates in cell cycle control modu-
lating E2F pathway, and mutations in this gene can be
found in various cancer databases [38]. Moreover, a recur-
rent frameshift mutation in TFDP1 has been reported in
colorectal cancer [39]. In addition, 8q11.1q24 region,
which is amplified in the three samples analysed by CGH,
includes among other genes MYC, a key inductor of
proliferation which has been shown to be commonly
amplified in ovarian cancer [11]. Another important
pathway consistently affected in all samples analysed was
microtubule-based movement. KIF21A, one of these
mutated genes, has been shown to be down regulated in a
murine lung cancer model due to the aberrant methyla-
tion of its promoter [40]. It has also been reported,
together with other cytoskeleton-associated proteins, to
be implicated in breast, cervix and osteosarcoma cells
Fig. 5 Network analysis of signaling pathways affected by multiple gene mutation. Functional annotation was performed for variants with
a possible negative consequence detected by whole-exome sequencing using David protocols (see M&M). Network analysis by Cytoscape
tool revealed signaling pathways containing multiple mutated genes. Functional nodes annotated by Biocarta, Gene Ontology, KEGG or
Reactome terms are represented in squared nodes. Mutated genes are represented in circles, which colour indicates the samples in which
they are mutated (see node fill color mapping)
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survival [41]. Microtubule-based movement is essential
for chromosomal partitioning and segregation, an import-
ant role in ovarian HGSC, characterised by wide genomic
and chromosomal aberrations. This specific case shows
extensive copy number variations, with depletion of whole
chromosomes 4, 12 and 16. More unexpected was the
alteration of lipid metabolism. Mutations related to lipid
metabolism were mainly shared by the three samples
analysed by WES, suggesting a driver role for this path-
way. Some of the mutated lipid-related genes have been
reported to be involved in tumor progression in other
types of tumors. ACADVL expression is down regulated in
adrenocortical tumors [42]. Germline polymorphisms in
the estradiol-metabolism related enzyme SULT2B1 have
been associated to prostate cancer risk [43], and its
expression has been shown to be reduced in this type of
tumor [44]. PCYT2 activity has been shown to be
increased in breast cancer cells, enabling them to adapt to
metabolic stress [45], and TRERF1 acts as a cell cycle
inhibitor in breast cancer cells through the modulation of
progesterone receptor [46]. Altogether, this data supports
the hypothesis of a key role for lipid metabolism deregula-
tion in this case of ovarian HGSC. Interestingly, TCGA
expression data regarding ovarian cancer shows that the
expression of lipid metabolism-related genes is consist-
ently altered in this type of tumor [47]. As a steroid
hormone producing organ, steroid metabolism must be
tightly regulated in the ovary. Besides, it is well known
that lipogenesis is increased in cancerous cells in compari-
son to normal cells. In addition, lipid catabolism inhibits
glycolisis, the major energy source used by malignant cells.
Moreover, TP53 has been shown to be a key regulator of
lipid metabolism, inhibiting its anabolism and promoting
its catabolism through the regulation of gene expression
[48]. Thus, lipid metabolism could represent an important
metabolic pathway related to ovarian cancer progression,
constituting a new therapeutic target for this type of
cancer, frequently resistant to conventional therapy.
Nevertheless it is important to take into consideration
that this study has been carried out with a single patient.
In order to strengthen its conclusions about the conse-
quences of intra-tumoural heterogeneity in HGSCs, and
also to gain a deeper understanding of the biology of
p53-null HGSCs, an in-depth study considering a larger
number of patients should be undertaken.
Conclusions
Overall, these data shed light on the clonal evolution of the
distinct tumor regions and thus on at least some of the
genes that may be implicated in its progression and recur-
rence, and highlights the importance of considering intra-
tumor heterogeneity when carrying out genetic and gen-
omic studies, especially when these are aimed to diagnostic
procedures or to uncover possible therapeutic strategies.
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